Statements (32)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
PARP inhibitor |
| gptkbp:administeredBy |
oral
|
| gptkbp:approvalYear |
2018
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
L01XX60
|
| gptkbp:CASNumber |
1207456-01-6
|
| gptkbp:contraindication |
pregnancy
|
| gptkbp:developedBy |
gptkb:Pfizer
|
| gptkbp:hasMolecularFormula |
C19H14F2N6O
|
| https://www.w3.org/2000/01/rdf-schema#label |
Talazoparib
|
| gptkbp:KEGGID |
D10813
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:marketedAs |
gptkb:Talzenna
|
| gptkbp:mechanismOfAction |
inhibits PARP1 and PARP2
|
| gptkbp:PubChem_CID |
gptkb:CHEMBL1800631
24958200 DB12021 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
gptkb:anemia
nausea fatigue neutropenia thrombocytopenia |
| gptkbp:synonym |
gptkb:Talzenna
BMN 673 |
| gptkbp:UNII |
Q3Z5X40X2J
|
| gptkbp:usedFor |
gptkb:cancer
BRCA-mutated breast cancer |
| gptkbp:bfsParent |
gptkb:PARP1
gptkb:PARP2 |
| gptkbp:bfsLayer |
7
|